New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD

BACKGROUND AND OBJECTIVES: To evaluate the pathophysiology of neuromyelitis optica spectrum disorder (NMOSD) and the therapeutic mechanism and levels of interleukin-6 (IL-6) blockade (satralizumab), especially with respect to blood-brain barrier (BBB) disruption with the new in vitro and ex vivo hum...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeshita, Yukio, Fujikawa, Susumu, Serizawa, Kenichi, Fujisawa, Miwako, Matsuo, Kinya, Nemoto, Joe, Shimizu, Fumitaka, Sano, Yasuteru, Tomizawa-Shinohara, Haruna, Miyake, Shota, Ransohoff, Richard M., Kanda, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529420/
https://www.ncbi.nlm.nih.gov/pubmed/34667128
http://dx.doi.org/10.1212/NXI.0000000000001076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529420/
https://www.ncbi.nlm.nih.gov/pubmed/34667128
http://dx.doi.org/10.1212/NXI.0000000000001076

Ejemplares similares